Silexion Therapeutics (SLXN) Share-based Compensation (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Share-based Compensation of $345000.0 for Q1 2026, up 1542.86% year-over-year from $21000.0 in Q1 2025, and up 807.89% quarter-over-quarter from $38000.0 in Q4 2025.
Silexion Therapeutics (SLXN) Share-based Compensation (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Share-based Compensation history runs 4 years deep, the most recent figure standing at $345000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 1542.86% year-over-year to $345000.0; the TTM figure through Mar 2026 stood at $458000.0 (down 92.17% YoY), while the FY2025 annual figure was $134000.0, down 97.71% from the prior year.
- Share-based Compensation for Q1 2026 stood at $345000.0, up from $38000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $5.8 million in Q3 2024, with the low at $21000.0 in Q1 2025.
- The 4-year median for Share-based Compensation is $34000.0 (2023), against an average of $585363.6.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 18018.75% in 2024, then slumped 99.34% in 2025.
- Silexion Therapeutics' Share-based Compensation stood at $34000.0 in 2023, then jumped by 16952.94% to $5.8 million in 2024, then plunged by 99.34% to $38000.0 in 2025, then soared by 807.89% to $345000.0 in 2026.
- Business Quant data shows SLXN's Share-based Compensation at $345000.0 in Q1 2026, $38000.0 in Q4 2025, and $38000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | 197,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 197,000.00 |
| Jun 30, 2026 | 197,000.00 |
| Mar 31, 2026 | 345,000.00 |
| Mar 31, 2026 | 345,000.00 |
| Dec 31, 2025 | 38,000.00 |
| Dec 31, 2025 | 38,000.00 |
| Sep 30, 2025 | 38,000.00 |
| Sep 30, 2025 | 38,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | 21,000.00 |
| Mar 31, 2025 | 21,000.00 |
| Sep 30, 2024 | 5.80 Mn |
| Sep 30, 2024 | 5.80 Mn |
| Jun 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 34,000.00 |
| Dec 31, 2023 | 34,000.00 |